Literature DB >> 11571323

Reversible ALS-like disorder in HIV infection.

A Moulignier1, A Moulonguet, G Pialoux, W Rozenbaum.   

Abstract

OBJECTIVE: To describe the clinical features, treatment, and outcome of six cases of HIV-1-associated ALS-like disorder.
METHODS: The authors reviewed patients with HIV infection with neurologic symptoms seen over a 13-year period. Patients were identified by using the El Escorial research diagnostic criteria defining three categories of certainty for definite, probable, or possible ALS. Clinical features, EMG, CSF, serum analyses, and imaging and virological studies were assessed.
RESULTS: Six patients with immunodepression (mean CD4(+) cells = 86.2/mm(3); mean age = 34 years) developed distal motor weakness mimicking a monomelic amyotrophy that subacutely progressed regionally or assumed a symmetric distribution on more than one region. EMG was characteristic of motor neuron disease with no multifocal conduction block. Causes other than HIV-1 were ruled out. The unusual rapid extension of the disease and the positive response to antiretroviral therapy suggest that ALS syndrome and HIV infection are etiologically related. HIV-1 might cause an ALS-like disorder by several mechanisms-via neuronal infection, by secretion of toxic viral substance, by inducing the immune system to secrete cytokines, or by inducing an autoimmune disease.
CONCLUSION: These cases suggest that the association between some motor neuron diseases and HIV infection is not coincidental but pathogenetically related and that ALS-like disorder should be considered an HIV-related neurologic complication.

Entities:  

Mesh:

Year:  2001        PMID: 11571323     DOI: 10.1212/wnl.57.6.995

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  27 in total

1.  Identification of active loci of a human endogenous retrovirus in neurons of patients with amyotrophic lateral sclerosis.

Authors:  Renée Douville; Jiankai Liu; Jeffrey Rothstein; Avindra Nath
Journal:  Ann Neurol       Date:  2011-01       Impact factor: 10.422

2.  Cholesterol-depleting statin drugs protect postmitotically differentiated human neurons against ethanol- and human immunodeficiency virus type 1-induced oxidative stress in vitro.

Authors:  Edward Acheampong; Zahida Parveen; Aschalew Mengistu; Noel Ngoubilly; Brian Wigdahl; Albert S Lossinsky; Roger J Pomerantz; Muhammad Mukhtar
Journal:  J Virol       Date:  2006-11-15       Impact factor: 5.103

Review 3.  Deficient RNA editing of GluR2 and neuronal death in amyotropic lateral sclerosis.

Authors:  Shin Kwak; Yukio Kawahara
Journal:  J Mol Med (Berl)       Date:  2004-12-29       Impact factor: 4.599

Review 4.  Amyotrophic lateral sclerosis: progress and prospects for treatment.

Authors:  Michel Dib
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 5.  Neuromuscular diseases associated with HIV-1 infection.

Authors:  Jessica Robinson-Papp; David M Simpson
Journal:  Muscle Nerve       Date:  2009-12       Impact factor: 3.217

6.  CSF proteomic fingerprints for HIV-associated cognitive impairment.

Authors:  Juliana Pérez Laspiur; Eric R Anderson; Pawel Ciborowski; Valerie Wojna; Wojciech Rozek; Fenghai Duan; Raul Mayo; Elaine Rodríguez; Marinés Plaud-Valentín; José Rodríguez-Orengo; Howard E Gendelman; Loyda M Meléndez
Journal:  J Neuroimmunol       Date:  2007-10-22       Impact factor: 3.478

7.  Flail arm-like syndrome associated with HIV-1 infection.

Authors:  A Nalini; Anita Desai; Simendra Kumar Mahato
Journal:  Ann Indian Acad Neurol       Date:  2009-04       Impact factor: 1.383

Review 8.  Retroviruses and amyotrophic lateral sclerosis.

Authors:  Tariq Alfahad; Avindra Nath
Journal:  Antiviral Res       Date:  2013-05-23       Impact factor: 5.970

Review 9.  Motor neurone disease.

Authors:  K Talbot
Journal:  Postgrad Med J       Date:  2002-09       Impact factor: 2.401

Review 10.  Bcl11b: A New Piece to the Complex Puzzle of Amyotrophic Lateral Sclerosis Neuropathogenesis?

Authors:  Matthew J Lennon; Simon P Jones; Michael D Lovelace; Gilles J Guillemin; Bruce J Brew
Journal:  Neurotox Res       Date:  2015-11-12       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.